# Sandy Srinivas

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandy-srinivas/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,439 |
| Field | Renal cell carcinoma treatment |
| h-index | 64 |
| i10-index | 164 |
| Last Known Institution | University of California, Irvine |
| OpenAlex ID | https://openalex.org/A5109140346 |
| Works | 332 |

## Researcher papers

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/prostate-cancer-version-2-2019-nccn-clinical-practice-guidelines-in-oncology/)
- [Prostate Cancer](https://scholariq.org/papers/prostate-cancer-2/)
- [Prostate Cancer, Version 1.2016](https://scholariq.org/papers/prostate-cancer-version-1-2016/)
- [Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/prostate-cancer-version-4-2023-nccn-clinical-practice-guidelines-in-oncology/)
- [NCCN Guidelines Insights: Prostate Cancer, Version 1.2021](https://scholariq.org/papers/nccn-guidelines-insights-prostate-cancer-version-1-2021/)
- [The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study](https://scholariq.org/papers/the-international-metastatic-renal-cell-carcinoma-database-consortium-model-as-a/)
- [Prostate Cancer, Version 2.2014](https://scholariq.org/papers/prostate-cancer-version-2-2014/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [University of California, Irvine](https://scholariq.org/institutions/university-of-california-irvine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.